01—Abstract
Summary
Summary of the 8-K filed November 6, 2023. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) filed an 8-K on November 6, 2023, primarily to disclose the cancellation of a pre-arranged trading plan by its Chief Commercial Officer, Arpa Garay.
This plan, known as the Garay 10b5-1 Plan, was established on August 24, 2023, with the intent to comply with Rule 10b5-1(c) for planned future stock sales. The cancellation occurred on November 6, 2023, subsequent to the company's Q3 2023 earnings release. Importantly, no shares were actually sold, and no options were exercised under this plan before its termination.
The sales were scheduled to commence no earlier than November 27, 2023. This disclosure is important for investors to understand executive trading activities and the absence of any actual stock sales under the specific plan that was cancelled. The filing also includes standard Regulation FD disclosure language.
02—Key points
Key Highlights
- Moderna's Chief Commercial Officer, Arpa Garay, cancelled her Rule 10b5-1 trading plan on November 6, 2023.
- The trading plan was established on August 24, 2023, intended for future stock sales.
- No shares were sold under the Garay 10b5-1 Plan prior to its termination.
- No stock options were exercised under the Garay 10b5-1 Plan before its cancellation.
- Scheduled sales under the plan were set to begin no earlier than November 27, 2023.
- The cancellation follows Moderna's disclosure of its third-quarter 2023 financial results.
03—Questions
Frequently Asked Questions
Why did Arpa Garay cancel her 10b5-1 trading plan?
The 8-K filing does not specify the reason for the cancellation. It only states that the plan was cancelled on November 6, 2023.
Were any shares actually sold by Arpa Garay under this plan?
No, the filing explicitly states that no shares of common stock were sold, and no options to purchase shares were exercised under the Garay 10b5-1 Plan prior to its termination.
Does this cancellation indicate a negative outlook on Moderna's stock?
The filing does not provide any indication of the company's or the executive's outlook. The cancellation of a 10b5-1 plan does not inherently signal a negative view, especially since no sales occurred and the reasons for cancellation are not disclosed.
When was the original trading plan established?
The Garay 10b5-1 Plan was adopted on August 24, 2023.
04—Continue